To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) has filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J).
The European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have issued joint guidance...
The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics Licence Application (sBLA) and granted priority review for Tecentriq (atezolizumab) to treat people with locally advanced or metastatic urothelial carcinoma (mUC).